Clinical Trial

Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia

Study acronym: FT14
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell transplantation (allo-SCT) in patients with Acute Myeloid Leukemia (AML) aged 40-65 years who are in complete remission.
Trial Details
NCT Number NCT07232953
Lead Sponsor Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Enrollment 82 participants
Start Date 2022-11-10
Primary Completion 2026-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-18